Sanofi

@sanofi · Paris · joined 27 Apr 2009

An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: https://t.co/mXmuqtkJaU

145 633Followers

214Following

7 354Posts total

14KViews on collected posts

Postingan terbaru

Sanofi@sanofi4 Aug

@sanofi Hi folks, when will the updated Nuvaxovid be available across Europe this summer/fall? 72 views · 1 likes · 0 reposts · 2 replies Open on X →

Sanofi@sanofi3 Aug

@sanofi It's pretty gross that you guys advertise on Fox News - given their attacks on public health. A pharma company should do better. 38 views · 0 likes · 0 reposts · 0 replies Open on X →

Sanofi@sanofi30 Jul

Our Q2 2026 results are now available. Read the full press release for detailed insights: https://t.co/ZijzaqKgmQ #SanofiResults $SAN $SNY https://t.co/EblAoFe5Ar

3.3K views · 15 likes · 6 reposts · 8 replies Open on X →

Sanofi@sanofi24 Jul

#NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ https://t.co/Pp1lF0swiy https://t.co/O1onn5cdvB

2.3K views · 8 likes · 4 reposts · 0 replies Open on X →

Sanofi@sanofi30 Jun

#NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: https://t.co/VOyUtc3ax4 https://t.co/bYcZR9jifm

3.8K views · 14 likes · 5 reposts · 0 replies Open on X →

Sanofi@sanofi23 Jun

#NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: https://t.co/gynO8BFmZi https://t.co/WJovWcdvBa

2.2K views · 9 likes · 5 reposts · 1 replies Open on X →

Sanofi@sanofi23 Jun

#NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ https://t.co/cZ6YH5IPhM https://

2.4K views · 15 likes · 4 reposts · 0 replies Open on X →

Dibandingkan akun berukuran sama

7 postingan dari 90 hari terakhir, dibandingkan dengan rentang 100K–1M pengikut. jangkauan biasa untuk ukurannya, reaksi lebih lemah dari kebanyakan.

Median tayangan2 282akun ini4 362median untuk 100K–1M

Jangkauan, %1.57%akun ini1.67%median untuk 100K–1M

Interaksi, %0.68%akun ini1.30%median untuk 100K–1M

Metrik	Akun ini	Median untuk 100K–1M	Rasio
Median tayangan per postingan	2 282	4 362	0.52×
Jangkauan (tayangan ÷ pengikut)	1.57%	1.67%	0.94×
Tingkat interaksi	0.68%	1.30%	0.53×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.4K23 Jun

2.2K

3.8K30 Jun

2.3K24 Jul

3.3K30 Jul

383 Aug

724 Aug

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.80%23 Jun

0.68%

0.50%30 Jun

0.53%24 Jul

0.89%30 Jul

0.00%3 Aug

4.17%4 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 1.30%.

What the audience does

Likes62.0%62 in total

Reposts24.0%24 in total

Replies11.0%11 in total

Bookmarks3.0%3 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.